


mRNA Applications

Accelerate Vaccine Development and Manufacturing

Analytical Solutions for mRNA Vaccines and Therapeutics


Eliminate mRNA analytical development bottlenecks and accelerate your path to market with off-the-shelf and custom mRNA solutions. A trusted partner among leading vaccine developers, InDevR offers a broad selection of products and services, including multiplexed assay development and integration during production and release of high-valency mRNA drug products, confirmation of protein expression, and serological testing in clinical and pre-clinical trials.

Capabilities



mRNA Assay Options

InDevR's VaxArray platform can help reduce operational burden and focus results by providing the flexibility to design custom assays for your unique targets and needs, including identity, quantification, and sample integrity.



Expert Services – A Trusted Partner for Bioanalytical Services

InDevR's Expert Services is a trusted partner of leading biopharmaceutical organizations worldwide, providing custom, cost-effective solutions to novel challenges faced in vaccine development and manufacturing. Whether you are struggling with an early-stage development bottleneck or looking for a tailored solution to help accelerate the scale of your project, our Expert Services team understands the challenges you face and are here to help.

1 Feasibility

Expert Services assess project feasibility for **proof of concept**

2 Prototype Kits

VaxArray user **evaluates custom kit** in-house

3 Performance Optimization

Microarray and assay optimized for customer assay performance KPIs

4 Manufacturing Transfer

Assay kit QC **documentation transferred** for production

Read About Our Solutions

Use the QR Code below to view InDevR's scientific publications.



Expert Services is ideal for organizations seeking innovative solutions to reduce the use of resources and time to market that can be integrated into the manufacturer's bioprocess in the complex vaccine and drug product development field.



InDevR's commitment to ensuring that the reagent kits are responsive to seasonal influenza strain changes saved our development team significant time and resources.

–Michael Schrader, CEO, Vaxxas Technologies



Explore Our Solutions at [InDevR.com](https://www.indevr.com) | Contact Us at sales@indevr.com